Daniel H. Shevrin

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Christopher J. Sweeney, Yu‐Hui Chen, Michael A. Carducci et al. · New England Journal of Medicine · 2015 · 2.8K citations · Full text

Medicine, Oncology, Urology +15

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

Christos E. Kyriakopoulos, Yu‐Hui Chen, Michael A. Carducci et al. · Journal of Clinical Oncology · 2018 · 1.1K citations · Full text

Medicine, Oncology, Urology +17

Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death

Rong Na, Shusen Zheng, Misop Han et al. · European Urology · 2016 · 341 citations · Full text

Medicine, Genetics, Oncology +17

Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012

Maha Hussain, Stephanie Daignault‐Newton, Przemyslaw Twardowski et al. · Journal of Clinical Oncology · 2017 · 210 citations · Full text

Medicine, Oncology, Urology +17

Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial.

Christopher J. Sweeney, Yu‐Hui Chen, Michael A. Carducci et al. · Journal of Clinical Oncology · 2014 · 188 citations

Medicine, Oncology, Pharmacology +17